Biopharmaceutical Industry
FDA drug dosage optimisation guidelines signal clinical trial reform
The FDA chooses drug optimisation as the preferred blueprint for cancer trials, departing from the maximum tolerated dose model.
The FDA chooses drug optimisation as the preferred blueprint for cancer trials, departing from the maximum tolerated dose model.